Neurofenix, a London, UK-based provider of a digital rehabilitation platform, raised $7M in Series A funding.
The round was led by AlbionVC, with participation from HTH, and InHealth Ventures.
The company intends to use the funds to build out its product line and invest in US expansion, including funding US clinical trials.
Founded in 2016 by Imperial graduates and Entrepreneur First alumni Guillem Singla Buxarrais (CEO) and Dimitrios Athanasiou (CTO), Neurofenix provides a neurological rehabilitation platform that uses sensors to improve patient outcomes. Its patient-focused approach combines sensor-based technology and telemedicine to improve recovery.
The company’s rehab program focuses on arm and hand therapy through its NeuroBall™ platform. Designed with input from over 300 therapists and patients, the tool is personalized to each patient based on their needs and enables them to perform increasingly challenging, repetitive movements to build up strength. The advanced sensors detect the smallest of movements so it can be used by impaired patients, while the wi-fi connected app has activities and digital games to motivate patients to use it regularly. Real-time feedback and leaderboards encourage them to continue.
The proprietary portal enables remote patient monitoring, proving popular in the US with occupational therapists who increased trust in digital care delivery during Covid-19.
FinSMEs
30/08/2022